Telix study shows cancer imaging drug may detect broader kidney tumors
Go back to Telix study shows cancer imaging drug may detect broader kidney tumors| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 10.00 -0.09 (0.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.09 | 52 Week High | $2.18 | |||
| Open | $10.47 | 52 Week Low | $0.30 | |||
| Day High | $10.47 | P/E | N/A | |||
| Day Low | $10.00 | EPS | $-3.32 | |||
| Volume | 140,826 | |||||
